Status:
UNKNOWN
IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids
Lead Sponsor:
Hotel Dieu Hospital
Collaborating Sponsors:
Sunnybrook Health Sciences Centre
Conditions:
Vitreoretinal Disease
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Intravitreal triamcinolone acetonide (IVTA) is a commonly employed treatment for various vitreoretinal disorders. However, approximately 23% to 50% of patients who receive IVTA develop ocular hyperten...
Eligibility Criteria
Inclusion
- Patients diagnosed with vitreoretinal disease for which IVTA has been chosen as treatment
Exclusion
- \< 18 years old
- Pregnancy
- Breast feeding
- hx of uveitis
- hx of neovascularization of the iris or anterior chamber angle
- hx of ocular herpes simplex keratitis
- hx of glaucoma
- Unable to provide informed consent
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00744666
Start Date
September 1 2008
End Date
July 1 2010
Last Update
August 6 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
2
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
3
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5
4
Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8